A new trading day began on Friday, with 10x Genomics Inc (NASDAQ: TXG) stock price down -0.53% from the previous day of trading, before settling in for the closing price of $15.08. TXG’s price has ranged from $12.95 to $51.22 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 27.69% over the last five years. Meanwhile, its annual earnings per share averaged 35.24%. With a float of $100.23 million, this company’s outstanding shares have now reached $106.98 million.
The firm has a total of 1259 workers. Let’s measure their productivity. In terms of profitability, gross margin is 65.89%, operating margin of -28.3%, and the pretax margin is -27.93%.
10x Genomics Inc (TXG) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Health Information Services Industry. The insider ownership of 10x Genomics Inc is 17.20%, while institutional ownership is 84.98%. The most recent insider transaction that took place on Nov 22 ’24, was worth 91,612. In this transaction Chief Executive Officer of this company sold 6,693 shares at a rate of $13.69, taking the stock ownership to the 872,574 shares. Before that another transaction happened on Nov 22 ’24, when Company’s insider sold 5,807 for $13.69, making the entire transaction worth $79,485. This insider now owns 339,897 shares in total.
10x Genomics Inc (TXG) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 35.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.39% during the next five years compared to -13.04% drop over the previous five years of trading.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
Here are 10x Genomics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.88. Likewise, its price to free cash flow for the trailing twelve months is 69.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.27 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
Analysing the last 5-days average volume posted by the [10x Genomics Inc, TXG], we can find that recorded value of 1.78 million was lower than the volume posted last year of 1.96 million. As of the previous 9 days, the stock’s Stochastic %D was 40.58%. Additionally, its Average True Range was 0.99.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 17.94%, which indicates a significant decrease from 35.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.25% in the past 14 days, which was lower than the 71.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.00, while its 200-day Moving Average is $19.47. Now, the first resistance to watch is $15.40. This is followed by the second major resistance level at $15.80. The third major resistance level sits at $16.10. If the price goes on to break the first support level at $14.70, it is likely to go to the next support level at $14.40. Now, if the price goes above the second support level, the third support stands at $14.00.
10x Genomics Inc (NASDAQ: TXG) Key Stats
With a market capitalization of 1.82 billion, the company has a total of 121,054K Shares Outstanding. Currently, annual sales are 618,730 K while annual income is -255,100 K. The company’s previous quarter sales were 151,650 K while its latest quarter income was -35,750 K.
